Pure Global AI
NCT06374186Not yet recruiting

Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City

COntinuous Glucose Monitoring, Contingency Management, and Motivational InTerviewing for Patients With TypE 2 Diabetes in Kansas City
University of Missouri, Kansas CityClinicalTrials.govbehavioral
Study focus
Disease/Condition
Type 2 Diabetes
Drug/Device/Intervention
Behavioral Intervention with financial rewards and coaching
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of Missouri, Kansas City
Location
Kansas City, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Apr 08, 2025
Enrollment
40 participants
Primary outcome

Time in target blood glucose range per CGM,Hemoglobin A1C

Summary

This study is evaluating a behavioral treatment program that uses diabetes coaching and
 financial rewards in addition to continuous glucose monitoring to improve diabetes management
 in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment
 program increases individual adherence to a diabetes treatment plan and improves blood sugar
 management.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06374186
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06374186 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Missouri, Kansas City and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.